Clinical data | |
---|---|
Trade names | Nipent |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a692004 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | 4% |
Metabolism | Hepatic, minor |
Elimination half-life | 2.6 to 16 hours, mean 5.7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.164.991 |
Chemical and physical data | |
Formula | C11H16N4O4 |
Molar mass | 268.273 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug. [2]
It is classified as a purine analog, which is a type of antimetabolite.
It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA. [3]
Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division ( mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.
Pentostatin is used to treat hairy cell leukemia. [4] It is given by intravenous infusion once every two weeks for three to six months.
Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. [5]
Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.
This is the original synthetic pathway although improvements were made.
Clinical data | |
---|---|
Trade names | Nipent |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a692004 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | 4% |
Metabolism | Hepatic, minor |
Elimination half-life | 2.6 to 16 hours, mean 5.7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.164.991 |
Chemical and physical data | |
Formula | C11H16N4O4 |
Molar mass | 268.273 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug. [2]
It is classified as a purine analog, which is a type of antimetabolite.
It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA. [3]
Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division ( mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.
Pentostatin is used to treat hairy cell leukemia. [4] It is given by intravenous infusion once every two weeks for three to six months.
Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. [5]
Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.
This is the original synthetic pathway although improvements were made.